Putting money behind real companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
that is false info at this stage in the game.
Dr. O'Banion is an internationally recognized scientist specializing in brain inflammation, epilepsy, brain radiation, and many neurological disorders. A veteran, in neuroscience, Dr. O'Banion's current research focuses upon pro-inflammatory cytokines and lipid mediators in traumatic brain injury, Alzheimer's disease, radiation injury, and psychiatric illnesses.
"We are very fortunate to welcome such a respected industry leader to serve on our Board," stated Bill Chaaban, President & CEO. "Dr. Obanion brings both clinical knowledge and business acumen to CEN Biotech. He has his finger on the pulse of cutting edge treatment for patients living with neurological conditions and will undoubtedly be a critical resource for our development and use of providing ground breaking medicinal cannabis solutions."
Dr. O'Banion is a distinguished leader at the University of Rochester Medical Center where he directs the NIH-funded Medical Scientist Training Program as Principal Investigator and serves as the Director of Medical Neurosciences courses. Dr. O'Banion is a research leader in individual and program grants with an outstanding record of NIH funding. His research in neuroinflammation provided the mechanistic underpinnings that led to the development of Vioxx and Celebrex, the COX-2 inhibitor pain relievers, for which he and colleagues were awarded U.S. patents. As a result he was appointed Assistant Professor of Neurology, and initiated research into neuroinflammation and its role in neurodegenerative disease.
Dr. O'Banion received both his M.D. and Ph.D. degrees from the University of Illinois School of Medicine, Champaign-Urbana, IL, where he graduated Summa Cum Laude and served as valedictorian for his graduation class.
About CEN Biotech CEN Biotech, Inc. was established in 2013 as a partially owned subsidiary of Creative Edge Nutrition (otc pink:FITX) (pinksheets:FITX) for the sole purpose of supplying the Canadian public with pharmaceutical-grade medical cannabis under the newly established Marihuana for Medical Purposes Regulations (MMPR). CEN Biotech Inc. has submitted a comprehensive application to become a licensed producer (LP) of dried marihuana for medicinal purposes and has received a ready-to-build approval from Health Canada.
Medical Advisory Board Chairman Dr. Sam Alawieh explains, "The general industry consensus continues to drive market focus on seed to sale and access to product as the critical elements for medical marijuana as an industry to succeed; we believe that science is the foundation required for success. It is our belief that strong science will layout the critical components of patients taking their medicine in the future. For example, having a real drug side effect profile or taking a strain with specific dosing customized for the patient based on a DNA saliva swab. Scientific studies are so desperately needed with cannabis and its active products".
Bill Chaaban, President & CEO adds, "We are assembling an unparalleled group of world renown physicians and researchers. Our company vision believes in innovation and research as the key to success and future profitability. Research and development will lead to the ownership of intellectual property. It is our belief that the true value in this industry lies in the ownership of intellectual property. To achieve this goal, we have put together divisions that we believe will allow us to execute our vertical integration vision from science to seed to sale."
Dr. Sam Alawieh continued to state, "The Research & Development Divisions Include: Genetic Engineering & Cloning, Genomic DNA Mapping & Strain Analytics, Extracts & Delivery Instruments, Pharmacogenetic & Clinical Trials, and Stem Cell & Tissue Proliferation.
"We are proud to announce a prominent research division, Stem Cell & Tissue Proliferation, adding Dr. Jonathan Lakey as the Chief Science Officer; an incredible expert in the field of medical research who will be researching initiatives in marijuana & hemp plant stem cells, plant cell cycles, tissue development acceleration, and the effects of Medical Marijuana on stem cell development including proliferation, differentiation down key developmental pathways," explained Dr. Sam Alawieh.
"I'm excited to be on this project and team; allowing for science to really dictate a responsible path of medicine which patients so desperately need." Dr. Lakey passionately described, "It is my goal to take the expertise and infrastructure I have developed over the years and apply it to the field of this research, strong evidence based science will address common misconceptions and provide scientific basis for our efforts. By studying effects of stem cells and differentiation we may gain key insight into pathways of disease treatments and wound healing. Bill Chaaban has done a great job emphasizing that this is the route necessary to take and I couldn't agree more."
Bill Chaaban stated, "From Day 1, we made the decision to overlook the principle of first to market because we believed in building from the ground up a model that is first to quality. The research division will allow us the ability to lay the necessary foundational upgrades driving the vision of eventually providing the best products to our patients."
Dr. Jonathan Lakey has a long history of innovative and ground breaking research leading to clinical changes in patient care and treatments. Dr. Lakey is an Associate Professor of Surgery and Biomedical Engineering at the University of California Irvine, California. He is a faculty member at the Sue and Bill Gross Stem Cell Center, a CIRM funded institute focused on stem cell research focused on translating technologies into clinical practice.
Dr. Lakey's innovative and groundbreaking research earned him a compelling list of academic accolades over his scientific career including the Meritorious Service Medal from the Governor General of Canada. Dr. Lakey has been published in numerous research articles for his incredible work in the field of diabetes research, stem cells and tissue transplantation with over 250 scientific publications, 30 book chapters and notable patents in wide ranging fields of biomedical research. Dr. Lakey is a widely sought after public and scientific speaker and has had several collaborations with biotechnology companies translating scientific discovery into clinical practice.
In the past week, site 1 has been groomed and is operationally prepared to grow medical cannabis. It is important to note that ground maintenance and cleanliness is an important component of GMP. Our team has conducted multiple dry runs and believes that we are operationally prepared to operate a GMP medical cannabis facility.
can u see it yet?
Michael has played a vital role in our company's strategic rollout, and his investment knowledge, business acumen and strong leadership is the underpinning for our future growth," commented Bill Chaaban, President & CEO. "As our company continues to define itself as a market leader, it is important to have a person of Michael's caliber and vision serve in the Vice Chairman role." Clark added, "I am excited to serve as Creative Edge Nutrition's new Vice Chairman, and I am honored to have been chosen among the boards deep talent bench."
Mr. Clark was Chief Executive Office of Clark Dodge Holdings, a multi-faceted financial holding company providing services that include investment banking for private equity, venture capital and late stage financing for public and private companies. He joins CEN Biotech with over 25 years of experience in the global securities industry having led the growth of several international servicing and financing companies including Fidelity and JP Morgan.
Mr. Clark has also served as Vice Chairman of Standard Charter Bank focusing on the Institutional market place. Prior to joining CEN Biotech, Mr. Clark held several senior positions including President of Fidelity Institutional Investments. He also served on their executive committee. Mr. Clark spent 15 years at JPMorgan where he ran the Division known as Worldwide Securities Services that service 22 Trillion dollars of investments More recently, Mr. Clark was Chief Executive Officer at Butterfield Fulcrum Group, a Hedge fund servicing company, from July 2010 to December 2011. Mr. Clark also served as Chairman of World Surveillance Group Inc. and Global Telesat Corp., from June 2010 until April 2012. He holds a double B.S. from SUNY Maritime College, an Executive M.B.A. from New York University, and an MS from USC in Quantitative Analysis and Statistics.
John Germinario, Chairman of Creative Edge Nutrition said, "I have had the pleasure of knowing David for almost fifteen years and I continue to be overly impressed with his qualifications and intellectual capacity in modern day medicine. With Bill's full support and the board's unanimous vote on Dr. Felten's appointment, it speaks volumes to the clear vision, focus, drive we uniformly have to establishing the highest industry standards in medicinal marijuana dedicated to access, accountability, quality and outcomes based medicine."
Mr. Germinario further commented, "We look forward to having David work along side our super star Sam Alawieh through his mentorship in guiding our company's continued infrastructure developments that is in line with our company vision. We are incredibly excited about the synergy in talents and believe Dr. Felten's world-class knowledge and skillset will improve our financial position and shareholder equity."
As the Chief Medical Director, Dr. David L. Felten, M.D. will join alongside our Chief Pharmacology & Acquisitions Officer, Dr. Sam Alawieh, Pharm.D. to partake in the launch of a fully operational medical board focused on good manufacturing practice, good laboratory practice, good clinical practice, compliance, vitamin, drug and naturally occurring pharmaceuticals research and development, treatment modality algorithms, and outcomes based reviews and analysis. Dr. Felten will bring scientific rigor and the highest of medical standards to the development, production, and distribution of all products from CEN Biotech.
Dr. David L. Felten was recently Vice President, Research, and Medical Director of the Research Institute at Beaumont Health System, and the founding Associate Dean for research at the Oakland University William Beaumont School of Medicine. He oversaw the Health System's research portfolio and actively participated in the development and commercialization of Beaumont's intellectual property. He established a state-of-the-art Core Molecular Laboratory and BioBank at Beaumont, strengthened the Beaumont Research Coordinating Center for oversight of multi-center clinical trials, and oversaw the conduct of all clinical translational research and basic research. Dr. Felten received a B.S. from the Massachusetts Institute of Technology in 1969, an M.D. from the University of Pennsylvania in 1973, and a Ph.D. in anatomy/neurosciences through the Institute for Neurological Sciences at the University of Pennsylvania in 1974. He has received numerous honors and awards, including the John D. and Catherine T. MacArthur Foundation Prize Fellowship, and two separate 10-year MERIT Awards from institutes (Aging, Mental Health) at the National Institutes of Health.
Previously, Dr. Felten was Dean of the School of Graduate Medical Education at Seton Hall University in South Orange, NJ, and was responsible for leadership of the residencies and fellowships in 5 large NJ hospitals, as well as graduate programs in allied health. He also served as Professor and then Chair of the Department of Neurobiology and Anatomy at the University of Rochester School of Medicine. Dr. Felten's research documented direct connections between the nervous system and the immune system, and established the foundations for the field of brain, behavior, and immunity (psychoneuroimmunology), and integrative medicine. He has published over 200 peer-reviewed publications and reviews, a majority of which focus on the links between the nervous system and the immune system, and the role these connections play in health and disease. Dr. Felten has served for many years on the National Board of Medical Examiners, helping to prepare questions for the US Medical Licensure Examinations. He also is author of the definitive neuroscience atlas, Netter's Atlas of Neuroscience, now in preparation for the third edition. He has served as the Chairman of the Scientific and Medical Advisory Board for Australian Cancer Technology (Avantogen), the Medingen Group, and The Clerisy Corporation, and is active in identification, evaluation, and commercialization of IP in medical and biological sciences, and biotechnology. He brings the same demanding scientific and medical standards to the development and understanding of products for commercialization as he does for his own research investigations.
Eric Nashman began in 2013 as marketing director for Creative Edge Nutrition and has since been actively cultivating the corporate marketing and branding strategy. Creativity and innovation are at the pinnacle of Eric's every move, infusing passion in every detail and at every step and expecting nothing but the highest standard. Eric has extensive experience in sales & marketing and business development that spans a wide variety of industries to include automotive, hospitality, office equipment, retail, franchise, manufacturing/wholesale . He has lent his talents to corporations such as Starwood Hotels and Resorts, Hilton Hotels, Ford Motor Company, Pitney Bowes, McDonalds and various mid-size corporations. Eric holds a Master of Business Administration degree from Wayne State University and a Bachelor's degree in psychology from the University of Alberta.
agreed, this otc company is a no brainer for any investors looking to make money long term. The DD speaks for itself. A google search speaks volume here...
NTEK - Sony - BestBuy - more to come
NTEK - I tried to tell people.
This company is going to right up there with the heavy weights. They took notice already, when will you as investors take notice, Do the dd and try not to buy shares,,,
OOO, going to be a great week here for NTEK. Lets see how the market reacts to partnering with SONY and BEST BUY. The latest PR showed up under BEST BUYS PR as well. Amazing story here developing.
MACD crossed zero, lets get a good run in here.
NTEK has tonnes of news in the pipelines coming in the coming weeks. Exciting times.
could have been...
who knows, doesn't matter either way to me. As long as they keep up all this execution we r golden.
amazing companies from the otc dont happen often, this is an amazing time to be a share holder.
get to watch the whole journey...
NTEK Chart
RSI at 61 at a steady climb north!
closed above the resistance at .063- .064 and it should now be a support level.
huge volume
next resistance is the 200dayMA at .085 and looks like it will be tested sooner then later.
macD creating some separation
thanks for all your DD and posts - I added to my position today.
wow, great stuff. ntek so legit
ive met both men and spoke to them individually. Just my thoughts...
fitx has their own technology but will honour their word for building #1 and try out edxc technology. But i dont think the relationship between the 2 will last too long...jmo
Wooooo, thanks for contributing to this forum. Top 3 stock in the OTC world easily. There is no doubt about this company rising to the elite class of 4k. Pretty much a dummy proof investment here.
4k Streaming - CONTENT CONTENT CONTENT!
Best Buy next to sell in stores...
Get your shares now and thank yourself later. Just spend an hour or so doing the DD and its easy to see.
amen - going to be a great week for fitx.
nice gains coming
going to be a good week here.
Joe Byrne for pres
U will see why soon.
wow kiling them demos.
lol - ntek going to be sold at best buy?
ntek ftw - can't stop them now
It looks to me more and more that "fitx" CEN bio is going to be the cream of the crop in this industry. Seems like most of these companies are winging it, or got a good grower and bad management or vice versa. Tweeds messed up many times already. They have huge money behind them but they will get surpassed by smarter companies quicker then most think. Other companies got great growers and will have great bud but they will lack in the research department in terms of it being medicine, the hows and whys with data to back it up. They will be more so capitalizing on the recreational users in the future. Organic bud will be very important to the marijuana purists. Does anyone know if CEN will be growing any organic strains? Companies like spwrf or whatever the ticker is are kind of a joke. I only heard of them because of the clowns promoting it which in my opinion is a bad look for that company to have such classless idiots pumping them. The industry will be huge and there is plenty of room for many companies to make millions. The market is there, has been for many many many years. Its time for the money to go back into society rather then a black hole. The more I refer back to the audio from the SH meeting February and recall the personal talks I had with Dr.Sam and with Bill... the more I realize they are bang on and have been bang on with every new piece of information comes out. I love the team thats been formed, very real people and very real professionals. Rare for a penny stock in the OTC. I am confident that in time, they will uplist... my guess would be the TSX as they are a little more flexible, just my guess though. But I do think there will be a restructure at some point, sooner then we think too. I really hope Bill keeps his word and get that doing with a buyback. But If he wants to up list quicker then a split of some sort would do the trick instantly. But I won't be surprised if he keeps his word and delivers on it again, he hasn't disappointed yet so... cross my fingers. As a long time player in the industry here in Canada, I truly think FITX will be in the top tier when all said n done. As for the growing patents, I know for a fact that they are not the only company who will be using techniques to get grow cycles done quicker. The doubters laugh at the possibility of that even being realistic and I laugh at the doubters. Like I said, I know its possible but they won't be the only company here that will be growing that fast. I would love to hear some opinions on the re structure....
cool, remind me in a year when they are at the stage fitx is at now
nice up trend on the chart.
yup, locked and loaded
NTEK flying...preparing for lift off.. chart looking good too
nice time to get in, the delay in license has put this stock on sale
a nice warning shot to all the little clowns that play tricks in the otc world
dont have a problem with Bill flashing his power to the little guys, Just a nice warning shot.
the wolfs a joke. Glad the little fish got put in his place.
yessssirrrr
nice stock here in the otc, skye the limit
Huge!
Being in the telecommunications industry, I can definitely respect what nano tech is making.
If they are first to the technology, thats game set match.
u r correct but recently they have everyone waiting. Like i mentioned before, my buddys facility in alberta has been #2 on the list to get inspected for months now
I had called the government posing as if I would want to obtain a license, back in early may I believe. They told me up to 6 months once my facility is ready to send someone out there. Theres a loooong list of applicants.
lol, its crazy.
NO NO NO, the sky isn't blue!
No, thats not the sun!
Yes folks, yes, the NP-1 is going to kill it. Revenues all day, all night.
NTEK greeeeennnn days ahead
I told everyone it can take up to 6 months and people called me a basher. Truth be told, thats the word I got from Health Canada themselves. The license will come, my friends plant in alberta is number 2 on HC's list at moment, and has been for quite a while now. HC is slacking.
Once they get license, then yes, money can be made, and its just another way to show to everyone how real this company is.
stay tuned